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In December 2016, the Opinion Group of the Bioethics and Law Observatory (OBD†) of the University 
of Barcelona launched a Declaration on Bioethics and Gene Editing in Humans analyzing the use of 
genome editing techniques and their social, ethical, and legal implications through a multidisciplinary 
approach. It focuses on CRISPR/Cas9, a genome modification technique that enables researchers to edit 
specific sections of the DNA sequence of humans and other living beings. This technique has generated 
expectations and worries that deserve an interdisciplinary analysis and an informed social debate. 
The research work developed by the OBD presents a set of recommendations addressed to different 
stakeholders and aims at being a tool to learn more about CRISPR/Cas9 while finding an appropriate 
ethical and legal framework for this new technology. This article gathers and compares reports that have 
been published in Europe and the USA since the OBD Declaration. It aims at being a tool to foster a 
global and interdisciplinary discussion of this new genome editing technology.
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INTRODUCTION
Biotechnology development advances rapidly 
and nowadays we are able to build scientific tools that 
years ago seemed like science fiction. This is the case of 
genome modification, which permits us to structurally 
alter the genetic background of humans and other living 
beings in order to decide on the characteristics of their 
descendants. Gene editing in humans, including the 
CRISPR/Cas9 (Clustered Regularly Interspaced Short 
Palindromic Repeats/Cas9) technique, already forms part 
of the molecular tools available to researchers and has 
increased its use among the scientific community over 
recent years.
Gene editing in humans has generated expectations, 
fears and many questions that deserve an interdisciplinary 
analysis and an informed social debate. There is a wide 
range of bioethical, political, and scientific positions 
which range from demanding a moratorium that would 
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paralyze this kind of research [1] to authorizing certain 
uses of gene editing in humans [2,3], passing through a 
gradualist paradigm [4]. Thus, it is necessary to clarify 
concepts, identify problems, and promote exchange 
between all stakeholders involved, such as universities, 
society, and science and technology systems, in order to 
articulate an optimal ethical and legal framework.
In this context, in December 2016, the Opinion 
Group of the Bioethics and Law Observatory (OBD) 
of the University of Barcelona (consisting of lawyers, 
biologists, philosophers, and physicians among other 
disciplines) launched its “Declaration on Bioethics and 
Gene Editing in Humans,” which analyses the use of 
genome editing techniques in human beings and its social 
implications through an ethical and legal approach. It also 
presents elements of reflection and makes proposals for 
specific actions based on current knowledge.
The ethical, social, and legal concerns of the CRISPR/
Cas9 technique (CRISPR from this point) have also been 
analyzed by other institutions such as the Nuffield Council 
of Bioethics [5], the Hinxton Group [6] and the UNESCO 
International Bioethics Committee [7]. This article aims 
at comparing and analyzing the documents that have 
been launched since the publication of the Declaration on 
Bioethics and Gene Editing in Humans developed by the 
Bioethics and Law Observatory. It analyses the document 
launched by the OBD and gathers the points of view that 
present the documents launched in 2017 by European 
and American scientific institutions regarding genome 
modifications.
In particular, this article gathers and compares the 
views of two European institutions (European Academies 
Science Advisory Council (EASAC) and The Company of 
Biologists) and two American institutions (The American 
College of Medical Genetics and Genomics (ACMG) 
and the National Academies of Science, Engineering, and 
Medicine).
CRISPR TECHNIQUE OF GENE EDITING IN 
HUMANS
Genome editing involves inducing a directed and 
specific modification in the DNA sequence of humans or 
other living beings. CRISPR is a gene editing technique 
that has exploded in popularity in the last few years. 
This tool has ancient roots, as it is an adaptation of the 
techniques used by bacteria to protect their cells from 
bacteriophages [8,9]. This archaic adaptive immune 
system present in some microbes is able to cleave the 
nucleic sequences of an invading virus [10]. Nowadays 
it can be used to cleave the genetic material of any 
organism and modify it [11]. CRISPR can be applied by 
using a piece of RNA called guide RNA (gRNA) that 
guides a Cas9 nuclease to a specific position of the DNA 
sequence [12]. Cas9 will not be able to recognize the 
position without the function of the protospacer adjacent 
motif (PAM) – a very short nucleic acid sequence that 
binds target DNA. Once they have arrived in the specific 
position, Cas9 nucleases can induce precise cleavage at 
genomic loci in humans. This cleavage is recognized by 
the cell’s DNA repair machinery and, while the damage 
is being repaired, corrections of the DNA sequences or 
addition of new hereditary material can be induced in this 
position [13].
CRISPR has a wide range of characteristics that give 
this technique a potential and interest unknown until now. 
In particular, four peculiarities deserve to be mentioned: 
Specificity, efficiency, accessibility, and versatility (Table 
1. Peculiarities of CRISPR) [14]. These characteristics 
make it a useful tool for developing precise genetic 
modifications in different cells, tissues, and organisms, 
including mammal and even human embryos, and it has 
rapidly become affordable for all science laboratories 
worldwide. In fact, data on the number of publications 
based on studies using this technique indicate an 
exponential growth in its use since 2012 [15]. Moreover, 
many start-ups that will commercially exploit this 
technology have been created.
A WIDE RANGE OF PERSPECTIVES 
REGARDING CRISPR
There is no global point of view regarding this tool 
that makes it possible to modify the genome of humans 
and other living beings. Not all countries and cultures 
share the same perspective regarding restrictions on the 
technology, but somatic cell gene therapy in humans is 
already being used in some countries [14].
While the EU has undertaken a bioethical debate 
about this technique (particulary the UK), in April 2015 
Chinese researchers announced that they had applied 
CRISPR to non-viable human embryos. In particular, 
they reported that the CRISPR system was able to cleave 
endogenous genes efficiently in human tripronuclear 
zygotes [16]. Recently, another research group from 
China has demonstrated that CRISPR is also effective as a 
gene-editing tool in available human embryos. However, 
they have highlighted the limitations that their results 
revealed and the need for further research [17].
In September 2015, a team of British researchers 
asked for authorization to apply CRISPR in embryos 
left over from in vitro fertilization that had been donated 
by their progenitors, with the aim of studying human 
preimplantation embryo development. In February 
2016, the British Human Fertilization and Embryology 
Authority (HFEA) gave its authorization, the first in the 
world for this type of research activity. This authorization 
allows research with healthy embryos, both newly 
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formed and up to 7 days old. Moreover, it makes clear 
that the embryos must be destroyed after the experimental 
process because it is strictly prohibited to transfer these 
genetically modified embryos to a woman or to use them 
for any other purpose. In contrast, the United States and 
China seem to have a more permissive legislative process 
regarding advances in biotechnology. The first protocol 
for gene therapy through CRISPR was approved in the 
United States in 2016 [18]; in China, the first Phase I 
clinical trial of gene therapy against lung cancer in humans 
is imminent. At the moment, gene therapy only considers 
the modification of the human genome in ex vivo somatic 
cells, which will then be reintroduced into the patient’s 
body. However, less than one year has passed between 
the publication of the gene editing of triploid human 
embryos developed in China and the introduction of this 
technology to cure serious cancers in patients that do not 
respond to chemotherapy and without the possibility of 
donors [14].
Due to the various applications of gene editing 
applied to human beings, it is impossible to give an 
overview of current international or national regulation. 
However, it is important to remark that the Council of 
Europe’s Convention on Human Rights and Biomedicine 
(which is open for signature by all states) establishes in 
its article 13 “Interventions on the human genome” that 
“An intervention seeking to modify the human genome 
may only be undertaken for preventive, diagnostic or 
therapeutic purposes and only if its aim is not to introduce 
any modification in the genome of any descendants” [19].
In this context, the bioethical and legal debate is 
particularly necessary in international forums, where 
scientists, experts in bioethics, and legal scholars can 
discuss and promote an ethical acceptable technology 
that solves social needs rather than individual interests. 
Due to the social impact of this technique and the wide 
range of points of view regarding this technology, in 
December 2016, the Bioethics and Law Observatory 
(OBD) of the University of Barcelona launched the 
Declaration on Bioethics and Gene Editing in Humans in 
order to guarantee a multidisciplinary, global, and flexible 
conception of gene editing in humans and analyze its 
ethical and legal framework.
THE DECLARATION ON BIOETHICS AND 
GENE EDITING IN HUMANS (OBD)
The Declaration on Bioethics and Gene Editing 
in Humans proposes a set of recommendations to 
different stakeholders. Firstly, it highlights the need 
for a framework based on respect for the precautionary 
principle. Within a gradualist position, the Opinion 
Group of the Bioethics and Law Observatory holds that 
genome editing techniques should proceed in phases. 
This means allowing the use of gene editing in basic 
research, approving therapeutic use in somatic cells, and 
assessing the possibility of approving germinal therapy 
for certain cases. In all cases, it should be applied for 
therapeutic purposes and not human enhancements. 
Sometimes the line between therapy and enhancement is 
not that obvious; thus, a clear definition of both concepts 
is necessary to better define the use of CRISPR.
The Declaration also suggests analyzing and 
revising current regulation at all levels, from the criminal 
code to assisted human reproduction law and the law 
on biomedical research. In this sense, an informed 
social debate is needed and decisions regarding the 
development of gene editing research and its application 
should be taken among different stakeholders. Thus, 
the research work emphasizes that technology should 
improve quality of life and, in this sense, decisions 
must be guided by the idea of the common good and 
not remain in the hands of financial powers. In contrast, 
patent policy and the current privatization process of 
Table 1. Characteristics of CRISPR.
Specificity CRISPR can induce genetic modifications at very specific points of the genome, whereas 
other transgenesis techniques have null or low precision. Specificity confers a high level of 
effectiveness on the genetic modification achieved and a very low incidence of undesired 
secondary effects.
Efficiency This gene editing technique is easily produced and has a high final percentage of genetically 
modified sequences in a specific location. 
Accessibility CRISPR is considered relatively simple to apply. It just requires a minimum knowledge of 
genetic manipulation techniques and a modest investment in infrastructure. In addition, the 
molecular tools required are accessible in public repositories more cheaply than requirements 
for other gene editing techniques. 
Versatility A wide range of variants of the molecular bases used in this technology have rapidly emerged 
due to the deep knowledge of this kind of base. This great variety makes it possible to exercise 
greater control over technique and to obtain an even greater range of molecular modifications 
that adapt to the needs of the researcher.
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Company of Biologists summarized the CRISPR genome 
editing system, discussed its potential applications and 
limitations in human pre-implantation embryos and the 
ethical considerations that this technique involves in 
a spotlight article launched in 2017 called “Towards a 
CRISPR view of early human development: applications, 
limitations and ethical concerns of genome editing in 
human embryos” [23]. Finally, in 2017 the National 
Academies of Science, Engineering and Medicine 
launched the Document “Human Genome Editing: 
Science, Ethics, and Governance” [24]. It was prepared 
by an interdisciplinary group that included biologists, 
bioethicists, and social scientists, and incorporated 
perspectives from potentially affected patient and 
stakeholder communities. The main strengths, limitations, 
ethical concerns, and recommendations raised by each 
document are summarized in Table 2.
DIVERGENCES AND COMMON POINTS
It is noteworthy that not all the reports are addressed 
to the same stakeholders; the focus of each one is different, 
making it difficult to compare them. However, their main 
common points can be seen and the main divergences can 
be discussed. OBD, EASAC, ACMG, the Community 
of Biologists, and the National Academies of Science, 
Engineering and Medicine reveal that CRISPR can be a 
valuable contribution to basic research. Additionally, the 
Community of Biologists and the National Academies of 
Science, Engineering and Medicine also explain in more 
detail the benefits of the gained knowledge for clinical 
applications (e.g. the treatment of infertility and stem-
cell-based regenerative medicine) although they point 
out that more investigation is needed. The Company of 
Biologists shows a less gradualist position than the others.
There is a global point of view that suggests that 
a better understanding of CRISPR is needed before its 
clinical application. The common limitations raised in all 
documents are the possibility of mosaicism (the presence 
of two or more populations of cells with different 
genotypes in one individual. It can occur when the cells 
divide before the genome editing takes place), off-target 
effects, and unknown long-term consequences. Moreover, 
the National Academies of Science, Engineering and 
Medicine highlight the effects on the human gene pool. 
Some genes that cause serious genetic diseases have 
been subject to positive selection to maintain the disease-
causing allele in the population because it produces some 
protection against infectious disease when present in 
one copy. If this gene is modified this protection will be 
lost. Apart from the technical limitations that CRISPR 
presents itself, the Community of Biologists mentions the 
restrictions in the analysis of the results (the time window 
for the analysis after gene editing in human embryos 
gene information are paradigmatic examples of practices 
that should not be followed. In this context, it is important 
to raise awareness about the possible existence of conflict 
of interests between scientists as researchers who 
look forward to an increase in global knowledge, and 
“entrepreneurs” who seek to maximize individual profits. 
Among its recommendations, the Declaration also says 
that it is necessary to have public policies to determine 
research priorities and ensure public participation and 
transparency in decision making accompanied by policies 
of open access to information.
In order to ensure the success of the recommendations 
proposed, there must be an effective system for evaluating 
and controlling research. Research ethics committees 
must review the integrity of research and innovation as 
well as its ethical, legal, and social implications [20]. The 
evaluation must be carried out by committees, whose 
members must have up-to-date training. Lastly, the 
report calls on the media and the public to get involved 
in an inclusive and informed social debate regarding 
genomic edition in humans. In order to achieve a non-
discriminatory debate, it is necessary to promote an 
informed public discussion at different levels involving 
citizens, researchers, policy-makers, and commercial 
sectors as well as the media. Science communicators 
must promote a responsible communication of science 
avoiding alarmism or exaggerated expectations regarding 
results.
GLOBAL AND INCLUSIVE DEBATE
After the Declaration on Bioethics and Gene 
Editing in Humans developed by the Bioethics and Law 
Observatory was launched, European and American 
institutions also presented documents focused on the 
analysis of CRISPR. Like the OBD’s declaration, they 
highlight strengths, limitations, ethical concerns, and 
recommendations that should be taken into account 
before applying CRISPR.
In March 2017, the European Academies Science 
Advisory Council (EASAC) launched a report called 
“Genome editing: scientific opportunities, public interests 
and policy options in the European Union.” This 
document is a broad synthesis of genome editing and 
aims at fostering an informed social debate about this 
issue [21].
The report of the American College of Medical 
Genetics and Genomics (ACMG) “Genome editing 
in clinical genetics: points to consider” was published 
online on 26 January 2017. It focuses on the analysis 
of the CRISPR system and suggests a set of points for 
consideration regarding the potential clinical application 
of genome editing addressed specifically to medical 
geneticists and other healthcare providers [22]. The 
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The research of the Bioethics and Law Observatory 
reveals that a global discussion regarding genome 
modification is needed for two main reasons. Firstly, there 
is increasing interest in the biological development of 
CRISPR and its social impact. Secondly, there is a shared 
view that CRISPR has both benefits and limitations 
and, therefore, further research is needed before its 
application. However, there is a wide range of opinions 
regarding the ethical and legal framework in which this 
research should be done and in which cases this technique 
should be applied.
OBD aims at opening a global discussion among 
different stakeholders such as universities, society, 
and science and technology systems on the application 
of gene editing in human beings. Moreover, we aim at 
moving one step further and propose some modifications 
to the Council of Europe’s Convention on Human Rights 
and Biomedicine. It was made precisely because of the 
fears of cloning and the possibilities of biotechnology 
and genetic engineering in the late 1990s, and it should 
be updated. It is necessary to face the current challenges 
that CRISPR poses in our century.
We think that a moratorium is completely useless in 
a very competitive scientific world with heterogeneous 
regulations and cultural environments. The example of 
China made us realize that the worst option is to ban. We 
need to start thinking both nationally and internationally 
about how to regulate this new technique that has changed 
the way we understand most of the things that we were 
discussing in the past century from a bioethical and legal 
perspective: for example, the nature of an embryo or the 
embryonic stem cells and their uses.
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